Literature DB >> 34894715

The prognostic role of miR-31 in colorectal cancer: the results of a meta-analysis of 4720 patients.

Milad Moloudizargari1, Jamal Rahmani2, Mohammad Hossein Asghari3, Ajay Goel1.   

Abstract

Aims: To study the association between miR-31 expression and clinical outcomes in colorectal cancer.
Methods: A systematic search was performed and 16 studies were found eligible. To calculate the combined hazard ratio (HR), the DerSimonian and Laird random-effects model was used.
Results: Pooled analysis revealed significant associations between high miR-31 expression and poor overall (HR: 0.68; 95% CI: 0.47-0.97; I2: 68.6%) and progression-free survival (HR: 0.49; 95% CI: 0.33-0.73; I2: 81.1%). High expressers were more likely to have a BRAF mutation. Therapeutic regimen and the mutational status significantly affected the observed associations.
Conclusion: We identified that high miR-31 expression is associated with poor overall survival and progression-free survival and has a significant predictive value for anti-EGFR response.

Entities:  

Keywords:  EGFR; KRAS; biomarker; cetuximab; survival; tumor

Mesh:

Substances:

Year:  2021        PMID: 34894715     DOI: 10.2217/epi-2021-0277

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  2 in total

Review 1.  MicroRNA-31: a pivotal oncogenic factor in oral squamous cell carcinoma.

Authors:  Xiaojiao Lin; Weizhou Wu; Yukang Ying; Jun Luo; Xuhui Xu; Linxia Zheng; Weili Wu; Suqing Yang; Shankun Zhao
Journal:  Cell Death Discov       Date:  2022-03-29

Review 2.  Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies.

Authors:  Paula Fernández-Palanca; Tania Payo-Serafín; Flavia Fondevila; Carolina Méndez-Blanco; Beatriz San-Miguel; Marta R Romero; María J Tuñón; Jose J G Marin; Javier González-Gallego; José L Mauriz
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.